<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Voyager Acquisition Corp Unit — News on 6ix</title>
<link>https://6ix.com/company/voyager-acquisition-corp-unit</link>
<description>Latest news and press releases for Voyager Acquisition Corp Unit on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 13 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/voyager-acquisition-corp-unit" rel="self" type="application/rss+xml" />
<item>
<title>Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG</title>
<link>https://6ix.com/company/voyager-acquisition-corp-unit/news/voyager-acquisition-corporation-announces-approval-of-its-business-combination-with-veraxa-biotech-ag-44</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp-unit/news/voyager-acquisition-corporation-announces-approval-of-its-business-combination-with-veraxa-biotech-ag-44</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>BROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) held the</description>
</item>
<item>
<title>Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG</title>
<link>https://6ix.com/company/voyager-acquisition-corp-unit/news/voyager-acquisition-corporation-announces-redemption-results-in-connection-with-its-business-combination-with-veraxa-biotech-ag-1</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp-unit/news/voyager-acquisition-corporation-announces-redemption-results-in-connection-with-its-business-combination-with-veraxa-biotech-ag-1</guid>
<pubDate>Wed, 11 Mar 2026 10:00:00 GMT</pubDate>
<description>BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) today announced that holders of 25,217,315 of the Company's Class A ordinary shares (“Class A shares”) exercised their right to redeem their shares for a pro rata portion of the funds in the Company's trust account, reflecting redemptions of approximately 99.67% of the total Class A shares outstanding in connection with the completion of the Company’s</description>
</item>
<item>
<title>VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC</title>
<link>https://6ix.com/company/voyager-acquisition-corp-unit/news/veraxa-biotech-voyager-acquisition-corp-125500291-1</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp-unit/news/veraxa-biotech-voyager-acquisition-corp-125500291-1</guid>
<pubDate>Thu, 17 Jul 2025 12:55:00 GMT</pubDate>
<description>ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, “Voyager” or the “SPAC”), announced today the filing of a registration statement on Form F-4 (the “Registration Statement”), which includes a preliminary proxy statement, with the U.S. Securities and Exch</description>
</item>
<item>
<title>VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies</title>
<link>https://6ix.com/company/voyager-acquisition-corp-unit/news/veraxa-biotech-voyager-acquisition-corp-050000947-1</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp-unit/news/veraxa-biotech-voyager-acquisition-corp-050000947-1</guid>
<pubDate>Wed, 23 Apr 2025 05:00:00 GMT</pubDate>
<description>VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical ProfilesCompany Pursuing Multiple Strategic Partnerships and Licensing Opportunities in 2025 and 2026Transaction Values VERAXA at a Pre-money Equity Value of $1.3 BillionActively Working with Existing and New VERAXA Investors to Raise a Crossover F</description>
</item>
<item>
<title>Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024</title>
<link>https://6ix.com/company/voyager-acquisition-corp-unit/news/voyager-acquisition-corp-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-warrants-commencing-on-or-about-september-30-2024</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp-unit/news/voyager-acquisition-corp-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-warrants-commencing-on-or-about-september-30-2024</guid>
<pubDate>Thu, 26 Sep 2024 04:00:00 GMT</pubDate>
<description>BROOKLYN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced that holders of the units sold in the</description>
</item>
<item>
<title>Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering</title>
<link>https://6ix.com/company/voyager-acquisition-corp-unit/news/voyager-acquisition-corp-announces-closing-of-dollar253000000-initial-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp-unit/news/voyager-acquisition-corp-announces-closing-of-dollar253000000-initial-public-offering</guid>
<pubDate>Mon, 12 Aug 2024 04:00:00 GMT</pubDate>
<description>BROOKLYN, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) today announced that it closed its initial public</description>
</item>
</channel>
</rss>